4:38 PM
Nov 13, 2017
 |  BC Extra  |  Clinical News

Nektar gains on NKTR-214/Opdivo combo data

Nektar Therapeutics (NASDAQ:NKTR) gained $4.60 (14%) to $37.10 on Monday after reporting interim response data from the dose-escalation Phase Ib portion of the Phase Ib/II PIVOT-02 trial evaluating NKTR-214 plus Opdivo nivolumab to treat advanced or metastatic solid tumors. Nektar presented the data over the weekend at the Society for Immunotherapy of Cancer meeting in National Harbor, Md.

In 11 evaluable treatment-naïve patients...

Read the full 292 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >